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Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a marker for acute kidney injury. We studied
whether serum NGAL predicts delayed graft function (DGF) and recovery of kidney function after transplantation.
Methods: Serum NGAL was analyzed using commercial ELISA and point-of-care (POC) (Triage®, Biosite) methods.
Serum samples were collected from 176 consecutive, deceased-donor kidney recipients just before transplant
surgery and on day 1 and 14 after transplantation. The first 132 samples were analyzed with both methods and the
remaining samples with the POC method.
Results: The correlation between the ELISA and POC methods was 0.89, p < 0.0001 and hence the POC method
was used for the remaining analyses. DGF was seen in 66/176 patients. Day 1 sNGAL was significantly higher in DGF
(588 ng/ml, SD 189.6) compared to early graft function (355 ng/ml, SD 166.2, p < 0.0001) and this difference persisted on
day 14. Day 1 sNGAL predicted DGF with an area under the curve (AUC) of 0.853 (CI 0.792-0.914, p < 0.0001). At the
optimal cutoff level of 423 ng/ml the sensitivity was 87% and the specificity 77%. In a multivariate analysis, day 1 sNGAL
emerged as an independent predictor of DGF. The sNGAL also predicted DGF lasting longer than 14 days with an AUC of
0.825 (CI 0.751-0.899, p < 0.0001). At the optimal cutoff level of 486 ng/ml, the sensitivity was 80% and specificity 75%.
Conclusion: Serum NGAL predicts clinically significant DGF and is useful in the care of kidney transplant recipients.
Keywords: Kidney transplantation, Delayed graft function, Serum NGAL, Point-of-care analysisBackground
Neutrophil gelatinase-associated lipocalin (NGAL) is a
small, positively charged iron-carrier protein expressed at
low levels in various epithelial cells (e.g. kidney, gastro-
intestinal tract, lungs) [1,2]. Due to its size and charge,
NGAL is freely filtered through the glomerulus. Normal,
steady state serum and urine NGAL concentration is ap-
proximately 20 ng/ml [3]. NGAL is markedly increased in
the serum and urine of patients with acute kidney injury
(AKI) [4-7]. Delayed graft function (DGF) is a form of AKI
and is associated with complicated posttransplant recovery
and an inferior 1-year outcome [8-15]. Prolonged DGF
has been reported to severely impair the long-term prog-
nosis of kidney transplantation [8,12]. The diagnosis of* Correspondence: maria.hollmen@helsinki.fi
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unless otherwise stated.DGF is currently made on clinical grounds days after
transplantation. However, we, and others, have shown that
urine NGAL also predicts DGF after deceased-donor kid-
ney transplantation [16-18]; moreover, there is data sug-
gesting that measuring serum/plasma NGAL soon after
transplantation is additionally valuable in predicting DGF
[19-24]. NGAL has also been shown to predict kidney in-
jury in liver transplant patients [25-27]. Despite these
promising results, the use of NGAL has not yet been
adopted in clinical transplantation.
The gold standard for NGAL analyses is immunoblotting.
However, this method is time consuming and not readily
available in clinical settings. Urine NGAL can also be mea-
sured using ELISA or a chemiluminescent microparticle
immonoassay (ARCHITECT®, Abbott). When testing NGAL
in the blood, ELISA or the recently introduced point-of-care
(POC) fluorescence-based immunoassay (Triage®, Bio-
site) can be used. This POC test enables fast, bedsidel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The correlation of sNGAL values using the ELISA and
POC methods. The measurements were performed on the day 0
and day 1 samples of 132 kidney-transplant recipients.
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of the POC method in NGAL analyses is still scarce.
Therefore, the aim of this study was to analyze how
the POC method correlates with the ELISA method in
measuring serum NGAL (sNGAL) and whether sNGAL
predicts the occurrence and duration of DGF.
Methods
Study design and patient population
This study is parallel to our previous work on urine
NGAL in the prediction of DGF [16]. We recruited 176
consecutive, adult, dialysis-dependent, deceased-donor
kidney transplant recipients between August 2007 and
August 2008. Here, we analyzed NGAL using the pro-
spectively collected serum samples from this patient
population. The Department of Surgery and the Ethics
Committee at Helsinki University Hospital approved the
study protocol. Written informed consent was obtained
from the recipients before enrolment.
The primary outcome variable was the onset of graft
function after transplantation, defined here, as it is most
widely defined, as the need for dialysis during the first
week after transplantation. However, in this classification,
patients requiring one dialysis due to fluid overload or
high potassium levels are also included in the DGF group.
Conversely, there are DGF patients with fluent urine out-
put from their native kidneys needing dialysis only after
the first week and they are thus excluded from the DGF
group. Therefore, to assess in more detail NGAL’s poten-
tial to predict DGF, we additionally performed a receiver
operating characteristic (ROC) analysis using the DGF
definition published by Halloran et al. consisting of plasma
creatinine concentration >500 μmol/l throughout the first
week, or oliguria of less than 1000 ml/24 hours for more
than two days, or more than one dialysis session needed
during the first week (28).
We collected the clinical data from the patients’ med-
ical records and the Finnish Kidney Transplant Registry
database, as previously described [16].
Sample collection and NGAL analyses
A pretransplant (day 0) blood sample was taken upon ar-
rival to the transplant unit. This sample was used to assess
serum NGAL concentrations in patients with end-stage
renal disease and as a reference value for the later time
points. Posttransplant samples were collected in the
morning following the transplant surgery (day 1) and
14 days after the transplantation (day 14). The samples
were immediately processed and stored at −70°C.
We used a commercial ELISA kit (BioPortoDiagnostics,
Gentofte, Denmark), as recommended by the manufac-
turer, for the NGAL analyses. The day 0, day 1, and day 14
samples were also analyzed using a point-of-care (POC)
fluorescence immunoassay NGAL kit and device (Triage®Biosite, San Diego, California, USA), as recommended by
the manufacturer. All measurements were performed in
duplicate and blinded to the sample sources and clinical
outcomes.
Statistical analyses
SPSS software version 20.0 (SPSS Inc., Chicago, Illinois,
USA) was used for the statistical analyses. All analyzed
variables were tested for distribution. T-test and ANOVA
were used for samples with normal distribution, and the
Mann–Whitney U and Kruskal-Wallis tests for analyses of
samples with skewed distribution. Chi-square and Fisher’s
exact tests were employed in analyses of contingency tables.
Bivariate correlations were analyzed using the Spearman
correlation coefficient for non-parametric, and the Pearson
correlation coefficient for parametric, measures of statistical
dependence. To assess DGF predictors, a multivariate ana-
lysis was used. A ROC analysis was performed to assess
NGAL’s potential to predict DGF and prolonged DGF. A p-
value <0.05 was considered significant.
Results
Pretransplant serum samples from 132 kidney recipients
and day 1 samples from 128 recipients were analyzed with
both ELISA and POC. The corresponding ELISA and
POC sNGAL values are shown in Figure 1. The mean
sNGAL was 506 ng/ml (SD 188.7) measured with ELISA,
and 536 ng/ml (SD 238.4) measured with POC. Their cor-
relation was 0.89, p < 0.0001. Since the correlation was
good we decided to use the sNGAL values measured using
the more practical POC method for the clinical analyses in
this study.
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kidneys, the mean pretransplant sNGAL was significantly
higher (822 ng/ml, SD 193.5) than that of recipients with
residual diuresis: the mean pre-transplant sNGAL was
697 ng/ml (SD 166.5) if the diuresis was 100–1000 ml/
24 hours and 561 ng/ml (SD 164.4) if the diuresis was more
than 1000 ml/24 hours (p < 0.0001). There was no signifi-
cant difference between hemodialysis and peritoneal dialysis
patients in this respect (data not shown). Pretransplant
NGAL was not affected by recipient age, gender, underlying
kidney disease, number of previous transplantations, mode
or length of pretransplant dialysis, or pretransplant plasma
creatinine (data not shown).
After transplantation, recipients with a urine output on
day 1 of more than 1000 ml had significantly lower
sNGAL levels (356 ng/ml, SD 168.1) compared to those
with a urine output of less than 1000 ml (593 ng/ml, SD
185.7, p < 0.0001). Recipients with a decrease in plasma
creatinine on day 1 compared to their pretransplant level
had significantly lower sNGAL levels (382 ng/ml, SD
196.0) compared to those with no change or an increase
in plasma creatinine on day 1 (547 ng/ml, SD 186.7, p <
0.0001). There were no significant differences in the other
parameters studied (data not shown).
The patient and transplantation characteristics ac-
cording to the onset of graft function are shown in
Table 1. DGF was seen in 66/176 patients and their oli-
guria lasted a mean of 12.1 days (SD 7.0). When com-
pared to the early graft function (EGF) group, the DGF
group’s donors were older, expanded criteria donors
[28] were more common, CIT longer, pretransplantTable 1 Patient and transplantation characteristics
Early gra
(EGF) n =
Mean recipient age years (SD) 50.4 (12.8
Gender, male (%) 65 (59.1)
Re-transplantation (%) 8 (7.3%)
Mode of dialysis, hemodialysis (%) 63 (57.3%
Time on dialysis before transplantation, days (SD) 788 (570.
Mean donor age years (SD) 49.1 (14.6
Expanded criteria donors 33 (30.0%
Mean cold ischemia time, hours (SD) 21.3 (3.5)
Day 1 mean plasma creatinine, μmol/L (SD) 464 (218.
Day 1 mean urine output, mL/24 hours (SD) 2504 (151
Number of rejections 5 (4.5%)
Mean eGFR, mL/min at 1 year (SD) 66.2 (20.1
1-year patient survival 99.1%
1-year graft survival 98.2%
eGFR = estimated glomerular filtration rate calculated using the MDRD equation. SD
conventional definition: i.e. the need for dialysis during the first week after transplahemodialysis more common than peritoneal dialysis,
and time on pretransplant dialysis longer.
Day 1 sNGAL was significantly higher in patients with
DGF (588 ng/ml, SD 189.6) compared to those with EGF
(355 ng/ml, SD 166.2, p < 0.0001) and this difference per-
sisted on day 14 (Figure 2). Day 1 sNGAL correlated with
the duration of DGF (R = 0.70, p < 0.0001). Day 1 sNGAL
correlated with day 1 plasma creatinine (R = 0.64, p <
0.0001), day 3 plasma creatinine (R = 0.76, p < 0.0001), day
7 plasma creatinine (R = 0.69 p < 0.0001), day 1 urine out-
put (R = 0.65, p < 0.0001), day 3 urine output (R = 0.51, p <
0.0001), and day 7 urine output (R = 0.39, p < 0.0001).
A ROC analysis was performed to assess the potential of
day 1 sNGAL in predicting DGF. The area under the curve
(AUC) was 0.853 (CI 0.792-0.914, p < 0.0001) (Figure 3). At
the optimal cutoff level of 423 ng/ml, the sensitivity was
87% and the specificity 77% (the sensitivities and specific-
ities for different cutoff levels are shown in Table 2). In
comparison, urine output on day 1 predicted DGF with an
AUC of 0.962 (CI 0.922-0.979, p < 0.0001). At the optimal
cutoff level of 1035 ml/24 h, the sensitivity was 92% and
the specificity 81%. Moreover, day 1 plasma creatinine pre-
dicted DGF with an AUC of 0.785 (CI 0.718-0.852, p <
0.0001). At the optimal cutoff level of 523 μmol/l, the sensi-
tivity was 74% and the specificity 71%. The change in
plasma creatinine from the pretransplant level to the day 1
level predicted DGF with an AUC of 0.769 (CI 0.696-0.843,
p < 0.0001). At the optimal cutoff level of 68 μmol/l, the
sensitivity was 76% and specificity 55%.
Additionally, we repeated the ROC analysis for sNGAL
on day 1 after classifying the patients according to theft function
110 (62.5%)
Delayed graft function
(DGF) n = 66 (37.5%)
p-value
) 54.4 (13.2) NS
45 (68.2) NS
7 (10.6%) NS
) 51 (77.3%) 0.009
3) 953 (608.7) 0.029
) 56.2 (11.5) 0.001
) 36 (54.5%) 0.001
22.9 (3.7) 0.003
4) 207 (114.4) <0.0001
4.8) 502 (538.5) <0.0001
5 (7.5%) NS
) 54.8 (20.5) <0.0001
98.5% NS
89.4% 0.015
= standard deviation. Delayed graft function defined according to the
ntation. Expanded criteria donor status defined according to Port et al. [28].
Figure 2 The sNGAL concentration at day 0, day 1, and day 14 in
early graft function (EGF) and delayed graft function (DGF) groups
measured using the point-of-care (POC) method. The results are
expressed as means (+standard deviation, SD). DGF is defined as the
need for dialysis during the first week after transplantation.
Table 2 The sensitivities and specificities at different
cutoff levels for day 1 sNGAL in predicting delayed graft
function (DGF)
Day 1 sNGAL ng/ml Sensitivity Specificity
71 1.00 0.00
199 0.97 0.11
302 0.95 0.41
423 0.87 0.77
607 0.40 0.93
852 0.11 0.98
1131 0.00 1.00
sNGAL = serum neutrophil gelatinase-associated lipocalin. Delayed graft function
defined according to the conventional definition: i.e. the need for dialysis during
the first week after transplantation.
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sNGAL in predicting DGF was 0.908 (CI 0.860-0.955, p <
0.0001) (Figure 4). At the optimal cutoff level of 426 ng/ml,
the sensitivity was 91% and the specificity 83%. The sensi-
tivities and specificities for different cutoff levels are shown
in Table 3.
Altogether, 10 patients were classified differently into
the DGF and EGF groups depending on whether the
conventional or the Halloran criteria for DGF were used
(Table 4). All of the patients who otherwise had prompt
function but required one dialysis (classified as DGF by
conventional criteria and EGF by the Halloran criteria)
had day 1 sNGAL less than 400 ng/ml. On the other
hand, those with poorly declining plasma creatinine butFigure 3 The ROC-curve in predicting delayed graft function
(DGF) defined as the need for dialysis during the first week after
transplantation. AUC, area under the curve; CI, confidence interval.with no dialysis performed (classified as EGF by conven-
tional criteria and DGF by the Halloran criteria) had day
1 sNGAL higher than 400 ng/ml.
In a multivariate analysis, we assessed the effect on the
occurrence of DGF of: donor age, donor creatinine, donor
eGFR, expanded criteria donor status, CIT, recipient age,
mode and length of dialysis before transplantation, change
in plasma creatinine from day 0 to day 1, day 1 urine out-
put, and day 1 sNGAL. Day 1 sNGAL and day 1 urine out-
put emerged as independent predictors of DGF, irrespective
of the DGF definition used (Tables 5 and 6).
The day 1 serum samples were drawn the morning after
transplant surgery, a mean 11.8 hours (SD 5.2) after the re-
perfusion of the graft. The time interval between reperfu-
sion and this day 1 sample varied from 2 hours to 24 hours;
it was 6 hours or less in 18 cases, 7 to 12 hours in 82 cases,
and more than 12 hours in 70 cases. DGF was predicted by
sNGAL well in all time interval groups, but the predictive
power was best in the group were the sample was drawn
less than 6 hours after reperfusion (Table 7).Figure 4 The ROC-curve in predicting delayed graft function
(DGF) defined using the Halloran et al. criteria for DGF [29].
AUC, area under the curve; CI, confidence interval.
Table 3 The sensitivities and specificities at different cut
off levels for Day 1 sNGAL in predicting delayed graft
function (DGF) using the Halloran definition for DGF
Day 1 sNGAL ng/ml Sensitivity Specificity
71 1.00 0.00
201 0.99 0.14
323 0.97 0.51
426 0.91 0.83
568 0.51 0.92
794 0.15 0.98
1131 0.00 1.00
sNGAL = serum neutrophil gelatinase-associated lipocalin. Delayed graft
function defined according to the Halloran criteria [29].
Table 5 Multivariate analysis of risk factors for delayed
graft function (DGF) defined using the conventional
definition
p-value
Donor age (years) 0.115
Donor plasma creatinine (μmol/L) 0.232
Donor eGFR (mL/min) 0.348
Expanded criteria donors 0.434
Cold ischemia time (hours) 0.364
Recipient age (years) 0.504
Mode of dialysis (hemodialysis or peritoneal dialysis) 0.058
Time on dialysis before transplantation (days) 0.488
Change in plasma creatinine from pretransplant to day 1 0.792
Recipient day 1 urine output (mL) <0.0001
Recipient day 1 sNGAL (ng/mL) 0.019
eGFR = estimated glomerular filtration rate calculated using the MDRD
equation, sNGAL = serum neutrophil gelatinase-associated lipocalin. Delayed
graft function defined according to the conventional definition: i.e. the need
for dialysis during the first week after transplantation. Expanded criteria donor
status defined according to Port et al. [28].
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of posttransplant oliguria, we divided the patients according
to the onset of graft function: <14 days (n = 150) or ≥14 days
(Prolonged DGF) (n = 26). There were significantly more
expanded criteria donors, day 1 creatinine was higher, and
day 1 urine output lower in the prolonged DGF group com-
pared to the group with onset of function <14 days
(Table 8). The mean day 1 sNGAL was significantly higher
in the prolonged DGF group (655 ng/ml, SD 217.6), com-
pared to those with the onset of graft function before day
14 (404 ng/ml, SD 183.2, p < 0.0001). Day 1 sNGAL pre-
dicted prolonged DGF with an AUC of 0.825 (CI 0.751-
0.899, p < 0.0001). At the optimal cutoff of 486 ng/ml, the
sensitivity was 80% and the specificity 75%. In multivariate
analysis, day 1 urine output and day 1 sNGAL emerged as
independent predictors for prolonged DGF (Table 9).
Discussion
We have recently shown that NGAL measured in the
urine of deceased organ donors is an independent risk
factor for prolonged DGF, suggesting that donor urineTable 4 Subgroup of 10 kidney transplantations categorized
Patient DGF definition Conventional
Halloran
1 EGF DGF
2 EGF DGF
3 EGF DGF
4 DGF EGF
5 DGF EGF
6 DGF EGF
7 DGF EGF
8 DGF EGF
9 DGF EGF
10 DGF EGF
EGF = early graft function, DGF = delayed graft function, UOP = urine output, Δcreat
sNGAL = serum neutrophil gelatinase-associated lipocalin.NGAL levels reflect the quality of the donor kidney and
its ability to tolerate ischemia-reperfusion injury during
transplantation [30]. Additionally, we, and others, have
found the urine NGAL of kidney transplant recipients to
be an early marker of DGF.
Serum/plasma NGAL has also been reported to predict
DGF in various studies. In one of these studies, NGAL
levels were analyzed using the POC method [21], whereas
the other studies had used the ELISA or the ARCHITECT
method. The first study by Kusaka et al. found that NGAL
levels were significantly higher in DGF patients than those
with immediate graft function, and in cases requiring
hemodialysis after transplantation the serum NGAL levels
were >400 ng/ml [19]. The study by Lebkowska et al. founddifferently depending on the used DGF definition
UOP 1d Δ creatinine d0-d1 sNGAL 1d
1750 −98 374
1710 −264 198
1670 −60 221
430 −272 604
2090 −74 722
2060 −319 759
1330 −67 971
100 −83 657
2350 −11 451
1030 +88 706
inine d0-d1 = change in plasma creatinine from pretransplant level to day 1,
Table 6 Multivariate analysis of risk factors for delayed
graft function (DGF) defined using the definition of
Halloran et al.
p-value
Donor age (years) 0.707
Donor plasma creatinine (μmol/L) 0.622
Donor eGFR (mL/min) 0.751
Expanded criteria donors 0.929
Cold ischemia time (hours) 0.063
Recipient age (years) 0.994
Mode of dialysis (hemodialysis or peritoneal dialysis) 0.102
Time on dialysis before transplantation (days) 0.721
Change in plasma creatinine from pretransplant to day 1 0.586
Recipient day 1 urine output (mL) <0.0001
Recipient day 1 sNGAL (ng/mL) <0.0001
eGFR = estimated glomerular filtration rate calculated using the MDRD
equation, sNGAL = serum neutrophil gelatinase-associated lipocalin. Delayed
graft function defined according to Halloran et al. [28]. Expanded criteria
donor status defined according to Port et al. [28].
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and urine output. Serum NGAL levels were and remained
significantly higher after transplantation in the DGF group
(mean 419 ng/ml) compared to the EGF group (mean
308 ng/ml) [20]. Bataille et al. found that pretransplant
plasma NGAL was high in all patients (mean 453 ng/ml).
After transplantation, plasma NGAL was significantly
higher in the DGF group (mean 571 ng/ml) compared to
the transplant patients with immediate graft function (mean
242 ng/ml). Indeed, plasma NGAL predicted DGF at
12 hours after transplantation with an AUC of 0.97. NGAL
concentration >400 ng/ml predicted DGF with a sensitivity
of 94% and specificity of 89% [21].
Furthermore, Lee et al. found that serum NGAL was
higher in transplant patients with DGF and that day 1
serum NGAL predicted DGF with an AUC of 0.86, sensi-
tivity of 79% and specificity of 50% [22]. In their more re-
cent study, Kusaka et al. found that sNGAL measured
using the ELISA method correlated well with sNGAL
measured using the ARCHITECT method. The sNGALTable 7 Time from reperfusion to day 1 serum sampling
Sample time after
reperfusion
Mean sNGAL
ng/ml EGF (SD)
Mean sNGAL
ng/ml DGF (SD)
<6 hours n = 9 n = 9
278 (78.8) 687 (239.4)
7 to 12 hours n = 46 n = 36
365 (159.5) 594 (169.2)
>12 hours n = 47 n = 23
321 (125.0) 526 (187.9)
EGF = early graft function, DGF = delayed graft function, AUC = area under the curve
conventional definition: i.e. the need for dialysis during the first week after transplaconcentration decreased markedly and rapidly after trans-
plantation in patients with immediate or slow graft func-
tion, but not in those with DGF or prolonged DGF. They
found that day 1 sNGAL 500 ng/ml predicted the need for
dialysis with an AUC of 0.99, sensitivity of 91% and speci-
ficity of 97%. Day 1 sNGAL of 700 ng/ml predicted pro-
longed DGF with an AUC of 0.93, sensitivity of 82%, and
specificity of 83%. In their study, day 1 sNGAL correlated
significantly with urine output, duration of DGF, and
serum creatinine on day 5 [23]. Mahdavi-Mazdeh et al.
found that serum NGAL levels were significantly higher in
the DGF and slow graft function groups compared to the
early graft function group. NGAL was able to identify pa-
tients with slow graft function from early graft function
unlike creatinine. They found that NGAL measured at
24 hours after transplantation best predicted DGF with an
AUC of 0.82 [24]. The findings in these studies, although
examining relatively small (n = 16 to 67) and heteroge-
neous kidney transplant patient populations (deceased-
donor, living donor, donation after cardiac death), are in
line with our results: serum NGAL predicts DGF and an
NGAL level of >400 ng/ml gives the best sensitivity and
specificity.
The ELISA test is well established and routinely used for
research. However, it is time consuming and prone to hu-
man error. When we began this project, only the ELISA
test was available; this test was thus used for the NGAL
analyses of the first 132 study patients. During the course
of the study a commercial POC kit for analyzing NGAL
levels from blood became available and was subsequently
used for the NGAL analyses of all the 176 study patients.
As the correlation between the NGAL measurements
using these two methods was acceptable and the POC
method is better suited for clinical work, we used the
POC test results in the evaluation of serum NGAL as a
predictor of DGF. Pretransplant sNGAL was measured to
investigate the serum NGAL levels in dialysis-dependent
patients, and these values were used as a reference for
sNGAL after transplantation. The only variable signifi-
cantly affecting pretransplant sNGAL was residual diur-
esis. Anuric or severely oliguric patients had substantiallyp-value DGF
vs EGF
ROC-analysis AUC, p-value, CI optimal
cut-off value, sensitivity, specificity
0.002 1.00, p = 0.001, CI 1.00-1.00
436 ng/ml, 100%, 100%
<0.0001 0.864, p < 0.0001, CI 0.783-0.946
420 ng/ml, 94%, 73%
<0.0001 0.920, p < 0.0001, CI 0.838-0.999
420 ng/ml, 91%, 83%
, CI = confidence interval. Delayed graft function defined according to the
ntation.
Table 8 Patient and transplantation characteristics according to the prolonged onset of graft function
Before 14 days At/later 14 days p-value
N 150 26
Mean age, years (SD) 51.8 (12.7) 52.6 (15.5) NS
First transplantation 138/150 (92.0%) 24/26 (92.3%) NS
Mode of dialysis, hemodialysis 95 (22.9%) 19 (73.1%) NS
Mean time on dialysis, days (SD) 842 (614.1) 899 (410.2) NS
Donor age, years (SD) 51.0 (14.3) 56.3 (SD 10.9) NS
CIT, hours (SD) 21.7 (3.7) 23.2 (3.4) NS
ECD donor status 53 (35.3%) 16 (61.5%) 0.008
Day 1 creatinine, μmol/L (SD) 508 (219.4) 676 (224.6) 0.002
Day 1 urine output, mL (SD) 1983 (1594.0) 392 (446.6) <0.0001
1-year graft survival 148 (98.7%) 19/26 (73.1%) <0.0001
1-year patient survival 149 (99.3%) 25 (96.2%) NS
SD = standard deviation, CIT = cold ischemia time, ECD = expanded criteria donor, defined according to Port et al. [28].
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is probable that, as the tubules no longer function, their
uptake of NGAL is limited and thus it is excreted in the
urine, causing the sNGAL concentration to decrease.
Furthermore, day 1 sNGAL predicted DGF well in the
ROC analysis. It also correlated with the length of DGF
and predicted prolonged DGF well. In the multivariate
analysis, day 1 sNGAL and day 1 urine output emerged
as independent predictors of DGF. In fact, day 1 urine
output predicted DGF better than sNGAL. Usually, diur-
esis is the easiest, and cheapest, method to assess the
onset of graft function. However, there are patients who
have copious diuresis and still experience DGF; in con-
trast, there are recipients with only moderate diuresis
but rapidly decreasing plasma creatinine without the
need for posttransplant dialyses.Table 9 Multivariate analysis of risk factors for prolonged
delayed graft function (DGF)
p-value
Donor age (years) 0.405
Donor plasma creatinine (μmol/L) 0.867
Donor eGFR (mL/min) 0.113
Expanded criteria donors 0.119
Cold ischemia time (hours) 0.416
Recipient age (years) 0.653
Mode of dialysis (hemodialysis or peritoneal dialysis) 0.861
Time on dialysis before transplantation (days) 0.867
Change in plasma creatinine from pretransplant to day 1 0.930
Recipient day 1 urine output (mL) 0.001
Recipient day 1 sNGAL (ng/mL) 0.042
eGFR = estimated glomerular filtration rate calculated using the MDRD
equation, sNGAL = serum neutrophil gelatinase-associated lipocalin. Expanded
criteria donor status defined according to Port et al. [28].Analysis of day 1 sNGAL enables a diagnosis of DGF
and prolonged DGF days before it is possible clinically. Al-
though there is no specific treatment for DGF, recognizing
the patients who have an increased risk of developing
DGF helps clinicians to optimize postoperative care and
avoid nephrotoxic treatments and interventions.
Our study does have certain limitations. First, it was a
single center study. Further, we had not standardized the
timing of the day 1 sampling, and the number of blood
samples taken very soon after reperfusion was low. The
confounding effects of surgery, dialysis, anesthesia, and dif-
ferent medications on sNGAL are also not known. Serum,
instead of the recommended plasma/whole blood, was used
for the POC analyses and we only studied one biomarker
instead of a panel of biomarkers. However, our study also
had several strengths. It is a nationwide study of 176 con-
secutive, adult, deceased-donor kidney recipients and, so
far, this is the largest study reporting sNGAL levels in kid-
ney transplant recipients. We analyzed the sNGAL levels at
the most significant time point after transplantation (day 1)
using two different methods and we analyzed the data using
two different, widely acknowledged definitions of DGF.
Conclusions
Our study clearly demonstrated that day 1 sNGAL pre-
dicted DGF well, even in cases where such a diagnosis
would be impossible on the basis of clinical signs alone.
Furthermore, day 1 sNGAL predicted prolonged DGF,
which affects the long-term success of transplantation.
The best performance of sNGAL in predicting DGF was
seen in the small group of cases with a timeframe of six
hours or less from reperfusion to blood sampling. In the
future, this finding should be confirmed with standardized
blood sampling. Therefore, on the basis of the results of
this study, sNGAL clearly has a place in the postoperative
surveillance of kidney transplant patients.
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